Becton, Dickinson and Company reports fiscal Q2 2026 results tomorrow morning with an unusual tension at its core: short sellers have been aggressively covering over the past month, yet this week they started rebuilding — and options traders are growing more defensive at the same time.
The month-long short-covering trend is the dominant structural story. Short interest collapsed from roughly 3.7% of free float in mid-March to a low near 1.9% in late April — a drop of more than 40% in shares shorted. That retreat was significant and fast. But the last five sessions have reversed the trend. SI % FF climbed from around 1.95% on April 22 back to 2.17% by April 28, a 6.5% jump over the week. Shorts who stepped away ahead of what looked like a cleaner setup are now cautiously rebuilding positions going into the print.
The borrow market reflects the same tentative tone. Availability remains ample — the lending pool is far from stressed, with cost to borrow at just 0.53% — meaning new short positions are cheap to initiate and easy to establish. CTB did tick up about 25% over the week, but from a very low base; the absolute rate remains well below levels that would signal squeeze risk. The borrow market is not flashing any alarm.
Options positioning has shifted more noticeably. The put/call ratio climbed to 0.51 on April 28, roughly 1.6 standard deviations above its 20-day average of 0.41. That's not an extreme reading — the 52-week high is 1.0 — but the direction is clear. Demand for downside protection has picked up meaningfully in recent sessions, a pattern consistent with investors hedging into an event they view as binary. The PCR was running as low as 0.30 through late March. The move since then tracks almost exactly with the stock's decline.
The Street's caution has a specific origin: February's earnings disaster. BDX fell 18.3% in a single session after its last quarterly report, then shed a further 15.5% over the following five days. That reaction is the prism through which every analyst move since has been made. Goldman Sachs reinstated coverage on April 10 with a Neutral rating and a $167 target — notable because it came after the stock had already fallen sharply, and the firm chose not to step in as a buyer. Piper Sandler lowered its target from $170 to $159 on April 17. The overall analyst consensus sits at Hold, with five Buys against nine Holds and no Sells. Targets range from around $159 to $202, all sitting well above the current price of $149.52 — implying meaningful upside on paper, but the Street's willingness to upgrade has been limited since February.
The bull case rests on the spinoff of the Lifesciences business sharpening BD's focus on higher-growth MedTech markets, plus a pipeline of key product launches including the HemoSphere Stream Module and BD Pyxis Pro. Today, the company also announced a quarterly dividend of $1.05 per share and unveiled a new vascular access technology, reinforcing its patient safety narrative into earnings. Bears point to tariff uncertainty weighing on the supply chain and an ongoing debt reduction programme constraining financial flexibility. EPS momentum scores rank in just the 13th percentile on a 90-day basis, though the 12-month forward EPS growth estimate ranks in the 97th percentile — a divergence that reflects near-term pressure against longer-term optimism. The P/E has compressed to 11.7x on a trailing basis, down nearly half a point over 30 days, while EV/EBITDA has also eased to 10.9x.
Peer performance this week offers limited comfort. GEHC fell 5.2% on the week, COO dropped 6.3%, and COCH declined 11.3%. STE was the lone exception, essentially flat. BDX's 4.6% weekly decline sits squarely in the middle of its peer group — no relative strength, no particular underperformance. The sector is simply under pressure, which means tomorrow's print will need to speak for itself rather than benefit from any tailwind.
With a history of severe single-day moves on earnings, short interest ticking back up, and the put/call ratio rising, the setup heading into Wednesday's report is one where the market is hedging rather than positioning for a surprise. The next question is whether the Q2 numbers — and any updated guidance on tariff exposure — do enough to shift that defensive posture.
See the live data behind this article on ORTEX.
Open BDX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
